Randolph Cooper is a Cardiology physician affiliated with Duke University. OpenAlex indexes 20 publications with 295 citations (h-index 9); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2800 Blue Ridge Rd Ste 400
Raleigh, NC 276076477
Telephone
919-787-5380Provider last certified this registry record 1 Apr 2021.
Clinical trials
- REFLEx Study (ENDOTAK RELIANCE G Evaluation of Handling and Electrical Performance
Sponsor: Boston Scientific Corporation
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)Program year20251 payment
- Abbott LaboratoriesProgram year20242 payments
- iRhythm Technologies, Inc.Program year20242 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
74.4%Beta blocker26.7%Metoprolol Succinate35%Metoprolol Tartrate25%Carvedilol22%Sotalol15%Atenolol2%Bisoprolol-Hydrochlorothiazide1%Part D<11 patientsAntiarrhythmic12.7%Flecainide Acetate56%Amiodarone Hcl39%Dofetilide2%Disopyramide Phosphate2%Part D<11 patients+ 16 more classes in this area
Blood & clotting
24.2%Factor Xa inhibitor21.1%Eliquis79%Xarelto21%Part D≥181 patientsVitamin K antagonist1.8%Warfarin Sodium100%Part D≥32 patients+ 1 more class in this area
Metabolism & gastrointestinal
0.9%Potassium supplement0.9%Potassium Chloride100%Part D≥15 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Can Early Timed Internal Atrial Defibrillation Shocks Reduce the Atrial Defibrillation Threshold?
Pacing and Clinical Electrophysiology
1999 - The role of waveforms and lead configurations for internal artial cardioversion
Herzschrittmachertherapie + Elektrophysiologie
1998
Similar KOLs
Other experts from the same institution or the same specialty.
Robert Califf, MD
Duke University
Pamela Douglas, MD
Duke University
Adrian Hernandez, MD
Duke University
John Perfect, MD
Duke University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”